[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Whitehawk Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100627144","phase-1-study-evaluating-the-safety-and-efficacy-of-hwk-007-a-ptk7-directed-antibody-drug-conjugate-in-participants-with-advanced-solid-tumors-100627144",false,"NCT07444814","Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\nHave one of the following solid tumor cancers:\n\n1. Monotherapy escalation and backfill cohorts:\n\n   1. non-squamous EGFR-Wt NSCLC\n   2. Endometrial carcinoma\n   3. Platinum Resistant Ovarian Cancer\n2. Monotherapy expansion cohorts:\n\n   1. Non-squamous EGFR-Wt NSCLC\n   2. Additional tumor indications to be defined in a future amendment\n\nExclusion Criteria:\n\n1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n2. Individual with history of carcinomatous meningitis\n3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n4. Individual with evidence of corneal keratopathy or history of cornea transplant\n5. Any serious unresolved toxicities from prior therapy\n6. Significant cardiovascular disease\n7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n8. History of pneumonitis\u002Finterstitial lung disease\n9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention","ALL","18 Years",{"count":19,"type":20},226,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.",[26,27,28,29,30,31,32],"Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Metastatic","Ovarian Cancer Metastatic Recurrent","Non-squamous EGFR Wt NSCLC","Platinum Resistant Ovarian Cancer","PROC",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,31,50],"PTK7","Ovarian cancer","Endometrial cancer","NSCLC","Lung cancer","Chemotherapy","ADC","Antibody-Drug-Conjugate","Solid tumor","Phase 1","Ovarian neoplasms","Endometrial neoplasms","Carcinoma, Non Small Cell Lung","Lung neoplasms","Gynecologic cancer","EGFR Wt NSCLC","DNA Topoisomerase I","RECRUITING","2026-03-26",{"date":54,"type":55},"2026-03-27","ACTUAL",{"date":57,"type":55},"2025-12-19",{"date":59,"type":20},"2028-12",{"name":61,"class":62},"Whitehawk Therapeutics, Inc.","INDUSTRY",12,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":76,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":63},"100629146","phase-1-a-study-of-muc16-directed-antibody-drug-conjugate-hwk-016-in-participants-with-advanced-solid-tumors-100629146","NCT07470853","A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  1. Monotherapy escalation, backfill and expansion cohorts:\n\n     1. Endometrial Carcinoma\n     2. Ovarian Cancer\n  2. Combination Escalation, Backfill and Expansion Cohorts a. Ovarian Cancer\n\nExclusion Criteria:\n\n1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n2. Individual with history of carcinomatous meningitis\n3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n4. Individual with evidence of corneal keratopathy or history of cornea transplant\n5. Any serious unresolved toxicities from prior therapy\n6. Significant cardiovascular disease\n7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)\n8. History of pneumonitis\u002Finterstitial lung disease\n9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",{"count":72,"type":20},265,[23],"HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group.\n\nThe study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.",[32,31,26],[27,26,32,77,78,40,43,42],"Ovarian","Endometrial","2026-03-09",{"date":81,"type":55},"2026-03-13",{"date":83,"type":20},"2026-03-15",{"date":85,"type":20},"2028-02",{"name":61,"class":62},""]